. Interaction of equal increments in arterial and portal vein insulin on hepatic glucose production in the dog. Am. J. Physiol. 273 (Endocrinol. Metab. 36): E972-E980, 1997.-We have previously shown that a selective increase of 84 pmol/l in either arterial or portal vein insulin (independent of a change in insulin in the other vessel) can suppress tracer-determined glucose production (TDGP) and net hepatic glucose output (NHGO) by ϳ50%. In the present study we investigated the interaction between equal increments in arterial and portal vein insulin in the suppression of TDGP and NHGO. Isotopic ([3-3 H]glucose) and arteriovenous difference methods were used in conscious overnight fasted dogs. A pancreatic clamp was used to control the endocrine pancreas. A 40-min basal period was followed by a 180-min test period, during which arterial and portal vein insulin levels were simultaneously and equally increased 102 pmol/l. Hepatic sinusoidal glucagon levels remained unchanged, and euglycemia was maintained by peripheral glucose infusion. TDGP was suppressed ϳ60% by the last 30 min of the experimental period. In contrast, NHGO was suppressed 100% by that time. Coincidentally, hepatic glucose uptake (net hepatic [ 3 H]glucose balance) increased significantly (ϳ4 µmol · kg Ϫ1 · min Ϫ1 ). The effects of simultaneous equal increases in peripheral and portal venous insulin were not additive in the suppression of TDGP. However, they were additive in decreasing NHGO as a result of an increase in the uptake of glucose by the liver. conscious dog; hepatic glucose uptake WE HAVE PREVIOUSLY SHOWN that a selective 84-pmol/l increase in either arterial or portal vein insulin (with no change of insulin in the other vessel) can suppress tracer-determined glucose production (TDGP) and net hepatic glucose output (NHGO) by ϳ50% (27). A selective 84-pmol/l increase in portal vein insulin decreased NHGO by 5.1 µmol · kg Ϫ1 · min Ϫ1 (relative to a control study) as the result of a suppression of hepatic glycogenolysis. A similar (84 pmol/l) selective increase in arterial insulin suppressed NHGO by 3.9 µmol · kg Ϫ1 · min Ϫ1 (relative to a control study). In that case, suppression of gluconeogenesis explained approximately one-third of the fall, as did the increase in hepatic sinusoidal insulin, which occurred as a result of the increase of insulin in the hepatic artery. The remainder of the fall was linked to a significant increase in lactate output from the liver, which resulted from a diversion of glycogenolytically derived carbon to lactate. This increase in net hepatic lactate output correlated temporally with a significant suppression of net hepatic nonesterified fatty acid (NEFA) uptake. On further investigation into the role of NEFA in the suppression of NHGO, we found that, when the NEFA levels were clamped during a selective 78-pmol/l increase in arterial insulin, net hepatic lactate output did not increase, net hepatic gluconeogenesis did not change, and the suppression of NHGO by peripheral insulin was halved (28).
conscious dog; hepatic glucose uptake WE HAVE PREVIOUSLY SHOWN that a selective 84-pmol/l increase in either arterial or portal vein insulin (with no change of insulin in the other vessel) can suppress tracer-determined glucose production (TDGP) and net hepatic glucose output (NHGO) by ϳ50% (27) . A selective 84-pmol/l increase in portal vein insulin decreased NHGO by 5.1 µmol · kg Ϫ1 · min Ϫ1 (relative to a control study) as the result of a suppression of hepatic glycogenolysis. A similar (84 pmol/l) selective increase in arterial insulin suppressed NHGO by 3.9 µmol · kg Ϫ1 · min Ϫ1 (relative to a control study). In that case, suppression of gluconeogenesis explained approximately one-third of the fall, as did the increase in hepatic sinusoidal insulin, which occurred as a result of the increase of insulin in the hepatic artery. The remainder of the fall was linked to a significant increase in lactate output from the liver, which resulted from a diversion of glycogenolytically derived carbon to lactate. This increase in net hepatic lactate output correlated temporally with a significant suppression of net hepatic nonesterified fatty acid (NEFA) uptake. On further investigation into the role of NEFA in the suppression of NHGO, we found that, when the NEFA levels were clamped during a selective 78-pmol/l increase in arterial insulin, net hepatic lactate output did not increase, net hepatic gluconeogenesis did not change, and the suppression of NHGO by peripheral insulin was halved (28) .
Selective increments in arterial and portal vein insulin thus bring about suppression of NHGO via different modes of action. Other studies investigating the effects of peripheral and portal vein insulin infusion on hepatic glucose production (HGP) were designed so that the level of the hormone changed at the liver and peripheral tissues simultaneously (1, 12, 13) . This prohibited an analysis of the interaction of the two signals. The goal of our study, therefore, was to determine whether the effects of equal increments in peripheral and portal vein insulin would be additive in suppression of HGP.
MATERIALS AND METHODS
Animal care and surgical procedures. Experiments were conducted on 11 conscious mongrel dogs (18-30 kg) of either sex that had been fed a meat and chow diet [34% protein, 46% carbohydrate, 14.5% fat, and 5.5% fiber based on dry weight; Kal Kan (Vernon, CA) beef dinner and Purina Lab Canine Diet No. 5006] once daily. The surgical facility met the standards published by the American Association for the Accreditation of Laboratory Animal Care, and the protocols were approved by the Vanderbilt University Medical Center Animal Care Committee.
Each dog underwent a laporatomy performed with the animal under general anesthesia (15 mg/kg pentothal sodium, presurgery, and 1% isoflurane inhalation anesthetic during surgery) 2 wk before the experiment. With the use of previously described sterile techniques (2) , Silastic catheters (0.03-in. ID; Dow Corning, Midland, MI) were placed into a splenic and jejunal vein for intraportal infusions as required. Catheters (0.04-in. ID) for blood sampling were placed in the left common hepatic vein, the hepatic portal vein, and the femoral artery, as described previously (10) . All catheters were filled with saline containing heparin (200 U/ml; Abbott Laboratories, North Chicago, IL), and their free ends were knotted before closure of the skin. Doppler flow probes (Instrument Development Laboratories, Baylor College of Medicine, Houston, TX) were placed around the hepatic artery and portal vein to determine hepatic blood flow, as previously described (24) . The Doppler leads, along with the catheters, were placed in a subcutaneous pocket before closure of the abdominal skin. The positions of the catheter tips were confirmed with autopsy.
Only dogs that had a leukocyte count Ͻ18,000/mm 3 , a hematocrit Ͼ35%, normal stools, and had consumed their daily food ration were used for a study. On the day of the experiment, after an 18-h fast, the catheters and flow probe leads were exteriorized, with the animal under local anesthesia (2% lidocaine; Astra Pharmaceutical, Worcester, MA). The contents of each catheter were aspirated, and the catheters were flushed with saline. The intraportal catheters (splenic and jejunal) were used for the infusion of insulin and glucagon (Lilly, Indianapolis, IN). Angiocaths (Deseret Medical, Becton-Dickinson, Sandy, UT) were inserted percutanously into the left cephalic vein for [3-3 H]glucose (NEN, Boston, MA) plus indocyanine green (Becton-Dickinson, Cockeysville, MD) infusion and into a saphenous vein for somatostatin (Bachem, Torrance, CA) plus insulin infusion. An angiocath was inserted into the right cephalic vein for peripheral glucose infusion. Each animal was allowed to rest quietly in a Pavlov harness for 30 min before the experiment was begun.
Experimental procedure. Each experiment consisted of a tracer and dye equilibration period (Ϫ140 to Ϫ40 min), a basal period (Ϫ40 to 0 min), and an experimental period (0 to 180 min). At Ϫ140 min, a priming dose of [3-3 H]glucose (25 µCi) was given and a continual infusion of [3-3 H]glucose (0.21 µCi/min) was begun to allow assessment of HGP. Constant infusions of indocyanine green (0.07 mg/min) and somatostatin (0.8 µg · kg Ϫ1 · min Ϫ1 ) were started simultaneously (t ϭ Ϫ140 min) via a leg vein to measure hepatic blood flow and to inhibit the endogenous secretion of insulin and glucagon, respectively. A constant intraportal infusion of glucagon (0.5 ng·kg Ϫ1 · min Ϫ1 ) was given to replace endogenous glucagon secretion. A constant infusion of insulin was given via a peripheral vein, and a variable insulin infusion was given via the portal infusion catheters to replace endogenous insulin secretion. The rate of the portal insulin infusion was adjusted to maintain preexisting plasma glucose levels. Once the plasma glucose level had been stabilized at a euglycemic value for 30 min, the basal sampling period was begun. The rate of [ 3 H]glucose infusion during the experimental period in the test group was adjusted to clamp the arterial plasma glucose specific activity at the value that preexisted during the basal period. This was not done in the control group because of the continued existence of a steady state for glucose.
Protocol 1: Combined simultaneous equal increase in peripheral and portal vein insulin group. During the basal period, the portal insulin infusion rate averaged 1.29 pmol · kg Ϫ1 · min Ϫ1 , whereas the peripheral insulin infusion rate was 0.48 pmol · kg Ϫ1 · min Ϫ1 . At 0 min, the portal insulin infusion was raised 0.54 pmol · kg Ϫ1 · min Ϫ1 and the peripheral insulin infusion was increased 1.5 pmol · kg Ϫ1 · min Ϫ1 . On the basis of our earlier studies (27, 28) , it was calculated that these changes in the insulin infusion rates would increase arterial and portal vein insulin levels ϳ84 pmol/l. These rates are in line with those used in our earlier studies (27, 28) , although, in the previous paper, they were mistakenly reported to be 10 3 greater than they actually were. Euglycemia was maintained during the experimental period using a variable glucose infusion given through a peripheral vein. In this way we were able to create simultaneous and equal increases in both the arterial and portal vein insulin concentrations.
Protocol 2: Control group. Control studies (Cont, n ϭ 5) were carried out as described in protocol 1 except that, on completion of the basal period, no changes were made in the site or rate of insulin delivery. The portal insulin infusion averaged 0.48 pmol · kg Ϫ1 · min Ϫ1 , and the peripheral insulin infusion was 0.48 pmol · kg Ϫ1 · min Ϫ1 . Glucose infusion was not required. In this way we controlled for changes in HGP, which might occur over time even in the absence of a change in insulin. The data from this group have been presented elsewhere (27) .
Arterial blood samples were taken every 10 min during the basal period and every 15 min during the experimental period. Portal and hepatic blood samples were drawn every 20 min during the basal period, 15 and 30 min after the initiation of the experimental period, and every 30 min thereafter. The arterial plasma glucose level was monitored every 5 min during the experimental period to assess glycemia. The total volume of blood withdrawn did not exceed 20% of the animal's blood volume, and two volumes of saline were given for each volume of blood withdrawn. No significant decreases in hematocrit occurred with this procedure (Յ5%). The arterial and portal blood samples were collected simultaneously ϳ30 s before collection of the hepatic venous sample in an attempt to compensate for transit time of glucose through the liver (14) and thus allow the most accurate estimates of net hepatic balance to be obtained.
Analytic procedures. The handling and immediate processing of blood samples has been described in our previous paper (27) . Blood samples were processed for the later determination of acetoacetate, ␤-hydroxybutyrate, glycerol, and lactate and the gluconeogenic amino acids alanine, glutamine, glutamate, glycine, serine, and threonine. Plasma samples were obtained for immediate analysis of glucose using the glucose oxidase method with a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA). Plasma samples were also processed for the later determination of [ 3 H]glucose, immunoreactive glucagon and insulin, NEFAs, and cortisol. All samples were kept in an ice bath during processing and then were stored at Ϫ70°C until they were assayed.
For the determination of plasma [ 3 H]glucose, 1-ml plasma samples were deproteinized with 5 ml of 0.067 N barium hydroxide and 5 ml of 0.067 N zinc sulfate (Sigma Chemical). A 5-ml aliquot of the supernatant was evaporated, the residue was reconstituted in 1 ml of water, and 10 ml of liquid scintillation fluid [EcoLite (ϩ), ICN Biomedicals, Irvine, CA] were added. Tritium in the sample was determined by liquid scintillation counting with a Beckman LS 5000TD. Whole blood metabolite concentrations were determined according to the methods developed by Lloyd et al. (18) for the Technicon Autoanalyzer (Tarrytown, NY) and Monarch 2000 centrifugal analyzer (Lexington, MA). Whole blood glutamine and glutamate concentrations were determined by the methods described in Wasserman et al. (30) . Plasma NEFAs were determined spectrophotometrically (Wako Chemicals, Richmond, VA). Immunoreactive insulin was measured using a doubleantibody procedure (23) . Immunoreactive glucagon was measured using a modification of the double antibody insulin radioimmunnoassay method (23) . Insulin and glucagon antibodies and 125 I tracers were obtained from Linco Research, St. Louis, MO. Blood gluconeogenic amino acids were determined by high-performance liquid chromatography separation (29) . Indocyanine green was measured spectrophotometrically at 810 nm to estimate hepatic blood flow, according to the method of Leevy et al. (17) . Blood acetoacetate concentrations were determined spectrophotometrically (26) . Enzymes and coenzymes for metabolic analyses were obtained from Boehringer-Mannheim Biochemicals (Germany) and Sigma Chemical.
Tracer calculations. Rates of tracer-determined total HGP (R a ) and tracer-determined glucose utilization were measured using a primed, continual infusion of [3-3 H]glucose. Data calculation was carried out using a two-compartment model described by Mari (19) using canine parameters reported by Dobbins et al. (11) . TDGP was calculated as the difference between R a and the exogenous glucose infusion rate.
Arteriovenous difference calculations. The NHGO and the net hepatic balance of gluconeogenic substrates were calculated using the formula [H Ϫ (0.28A ϩ 0.72P)] ϫ HF, where H, A, and P are the substrate concentrations in the hepatic vein, http://ajpendo.physiology.org/ femoral artery, and portal vein blood or plasma, respectively. HF is total hepatic flow of blood or plasma as estimated from indocyanine green, and 0.28 and 0.72 represent the approximate contributions of the hepatic artery and the portal vein, respectively, to total hepatic blood flow during somatostatin infusion (24) . With this calculation, a positive value represents net production by the liver, whereas a negative value represents net hepatic uptake. Plasma glucose values were multiplied by 0.73 to convert them to blood glucose values for the net hepatic balance calculation (22) . The data displayed in RESULTS were calculated with the use of indocyanine green-determined blood flows. The two (artery and portal vein) Doppler flow probes were both functional in only 6 of the 11 studies, precluding the use of Doppler-determined flows for the entire data base. Nevertheless, the Doppler flow data that were obtained confirmed that the ratio of arterial to portal blood flow that we used was correct. In previous studies (24), we have shown that the Doppler-and indocyanine greendetermined blood flows are not significantly different and, therefore, the method of flow determination used has little effect on the net hepatic balance calculation. Hepatic sinusoidal hormone concentrations were calculated using the formula 0.28A ϩ 0.72P, where A and P represent the hormone levels in arterial and portal plasma, respectively. Maximal gluconeogenesis from circulating precursors was calculated by summing the net hepatic uptake rates of all of the gluconeogenic precursors and dividing by two to account for the incorporation of the three carbon precursor into the six carbon glucose molecule. Lactate and the individual gluconeogenic amino acids were only considered for inclusion in the gluconeogenic uptake calculation (or total amino acid uptake) if net hepatic uptake was evident. The mean lactate and gluconeogenic amino acid data, on the other hand, represent the entire data base regardless of the sign of net balance. For calculation of total hepatic glucose uptake by the liver, net hepatic [3-3 H]glucose uptake [disintegrations · min Ϫ1 (dpm) · kg Ϫ1 · min Ϫ1 ] was divided by the arterial glucose specific activity (dpm/µmol). The calculation of hepatic glucose uptake assumes that uptake of glucose occurs before production and the resulting dilution of glucose specific activity across the liver is minimal. Because there is no difference between arterial and portal vein glucose specific activity and a minimal drop (6%) across the liver, the impact of this assumption is negligible. Failure of the hepatic sampling catheter occurred in one study in the combination group (Combo, n ϭ 6), thus precluding the calculation of net hepatic balance data in that experiment. Therefore, an n ϭ 5 value was used in the net hepatic balance calculations for each group, but the tracer data are based on n ϭ 6 for Combo and n ϭ 5 for Cont.
Statistics. The level of significance was P Ͻ 0.05 (2-sided test). The data were analyzed for differences on the basis of group-by-group comparisons and for changes from intragroup baseline values. Statistical comparisons between groups were calculated using two-way analysis of variance, and intragroup difference from baseline was calculated using one-way analysis of variance (Statview, Calabasas, CA). The Scheffé procedure and Fisher's protected least significant difference test for multiple comparisons were used post hoc when significant F ratios were obtained.
RESULTS

Effects of a combined increase in peripheral and portal vein insulin.
When simultaneous increments in arterial and portal insulin were brought about, the arterial insulin level rose from 66 Ϯ 9 (basal) to 168 Ϯ 13 pmol/l by the last 30 min of the study (Fig. 1) and the portal insulin level increased similarly (210 Ϯ 47 to 312 Ϯ 45 pmol/l). Sinusoidal insulin therefore increased from ϳ170 (basal) to 272 pmol/l (last 30 min). The hepatic sinusoidal glucagon level fell slightly (ϳ10%), whereas the arterial plasma glucose concentration and plasma glucose specific activity remained unaltered (Table 1) . TDGP fell from 12.4 Ϯ 0.7 to 7.9 Ϯ 0.9 µmol · kg Ϫ1 · min Ϫ1 by 30 min into the experimental period and was suppressed to 5.3 Ϯ 0.8 µmol·kg Ϫ1 ·min Ϫ1 by the last 30 min of the study (Fig. 2 , P Ͻ 0.05). NHGO fell from 9.8 Ϯ 2.2 to 4.0 Ϯ 1.2 by 30 min and to 0.0 Ϯ 1.6 µmol · kg Ϫ1 · min Ϫ1 by the last 30 min of the study (Fig. 2 , P Ͻ 0.05). The rise in insulin increased whole body glucose utilization by more than twofold (Table 1 , P Ͻ 0.05). Interestingly, total hepatic glucose uptake (calculated from net hepatic [3-3 H]glucose balance) increased significantly from 1.2 Ϯ 0.1 (basal) to 4.3 Ϯ 0.2 µmol · kg Ϫ1 · min Ϫ1 by 1 h into the experimental period (P Ͻ 0.05) and remained elevated for the rest of the study (4.2 Ϯ 0.5 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Fig. 3) .
Arterial blood lactate levels ( Table 2) did not change during the course of the study. Net hepatic lactate (Fig. 4 ) rose significantly (P Ͻ 0.05), reaching 5.1 Ϯ 2.4 µmol · kg Ϫ1 · min Ϫ1 by 90 min, and then fell to 1.6 Ϯ 1.6 µmol · kg Ϫ1 · min Ϫ1 by the end of the study. The arterial blood glycerol level dropped ϳ35% (Table  2) , whereas arterial blood gluconeogenic amino acid levels dropped ϳ20% (Table 4) . Net hepatic uptake of glycerol declined slightly from 1.1 Ϯ 0.4 (basal) to 0.9 Ϯ 0.2 µmol · kg Ϫ1 · min Ϫ1 (Table 3 , P Ͻ 0.05), whereas the net hepatic uptake of the gluconeogenic amino acids did not change (4.5 Ϯ 0.7, basal, to 4.4 Ϯ 1.0 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Table 4 ). Total net hepatic gluconeogenic precursor uptake (including changes in net hepatic lactate uptake when such occurred) declined modestly from 7.6 Ϯ 1.7 (basal) to 5.7 Ϯ 1.2 µmol · kg Ϫ1 · min Ϫ1 (last 30 min, P Ͻ 0.05). This fall in hepatic gluconeogenic precursor uptake (1.9 µmol · kg Ϫ1 · min Ϫ1 ) could account for a drop of no more than ϳ1.0 µmol · kg Ϫ1 · min Ϫ1 in glucose production.
The arterial plasma NEFA level dropped significantly from 560 Ϯ 60 (basal) to 248 Ϯ 31 µmol/l (P Ͻ 0.05) by 1 h and remained suppressed thereafter (Table  2) . Net hepatic NEFA uptake showed a similar pattern of suppression (Fig. 5) . Arterial acetoacetate and ␤-hydroxybutyrate levels fell ϳ60% and ϳ30%, respectively (Table 2) , as the result of a fall in net hepatic ketone production from 1.4 Ϯ 0.2 (basal) to 0.8 Ϯ 0.2 µmol · kg Ϫ1 · min Ϫ1 (last 30 min, Table 3 ).
Control group. Neither arterial, portal, nor hepatic sinusoidal insulin levels changed over the course of the control experiments (Fig. 1) . Once again the hepatic sinusoidal glucagon level fell slightly (ϳ10%), whereas both the arterial plasma glucose concentration and the arterial plasma glucose specific activity remained unchanged (Table 1) . TDGP declined from 13.7 Ϯ 0.8 to 11.0 Ϯ 0.6 µmol · kg Ϫ1 · min Ϫ1 by the last 30 min of the experimental period (P Ͻ 0.05, Fig. 2 ). NHGO showed a similar decline (P Ͻ 0.05) from 10.5 Ϯ 0.7 (basal) to 8.4 Ϯ 1.1 µmol · kg Ϫ1 · min Ϫ1 (Fig. 2) , whereas whole body glucose utilization declined minimally over the course of the experiment (Table 1) . Hepatic glucose uptake (net hepatic [3-3 H]glucose balance) did not change (2.5 Ϯ 0.3, basal, to 2.4 Ϯ 0.6 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Fig. 3 ),
The arterial blood lactate level (Table 2) did not change even though net hepatic lactate output dropped modestly (8.0 Ϯ 2.9, basal, to 3.9 Ϯ 1.7 µmol·kg Ϫ1 ·min Ϫ1 , last 30 min, Fig. 4 ). Neither the arterial blood gluconeogenic amino acid levels (Table 4 ) nor the arterial blood glycerol level (Table 3 ) changed significantly. The net hepatic uptake of gluconeogenic amino acids increased slightly (4.3 Ϯ 0.2, basal, to 5.7 Ϯ 1.3 µmol · kg Ϫ1 · min Ϫ1 , last 30 min), whereas the net hepatic uptake of glycerol did not change (0.9 Ϯ 0.1, basal, to 0.9 Ϯ 0.3 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Table 3 ). As a result, total net gluconeogenic precursor uptake by the liver (including changes in net hepatic lactate uptake when such occurred) increased slightly from 5.2 Ϯ 0.3 (basal) to 6.9 Ϯ 1.4 µmol · kg Ϫ1 · min Ϫ1 (last 30 min, P ϭ 0.1) in the control study.
Arterial plasma NEFA levels (640 Ϯ 120, basal, to 670 Ϯ 94 µmol/l, last 30 min, Table 2 ), net hepatic NEFA uptake (2.2 Ϯ 0.5, basal, to 2.4 Ϯ 0.4 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Fig. 5 ), arterial acetoacetate and ␤-hydroxybutyrate levels (Table 2) , and net hepatic ketone production (1.0 Ϯ 0.2, basal, to 1.2 Ϯ 0.2 µmol · kg Ϫ1 · min Ϫ1 , last 30 min, Table 3 ) did not change significantly in the control group.
DISCUSSION
The combination of equal increases of 102 pmol/l in peripheral and portal vein insulin suppressed TDGP http://ajpendo.physiology.org/ Downloaded from ϳ60% and NHGO 100%. The difference in the two estimates of suppression can be explained by the ability of the combination of portal and peripheral insulin to increase hepatic glucose uptake, which would only be apparent in NHGO. Such an increase did not occur in response to a similar rise in arterial or portal insulin alone (27) . Hepatic glucose uptake must therefore have increased either because the liver sinusoidal insulin level was higher (60%) when the increments were brought about together or because the combination of the rise in portal vein and peripheral insulin has a unique effect. In response to the simultaneous and equal increases in arterial and portal vein insulin, TDGP decreased 4.4 µmol · kg Ϫ1 · min Ϫ1 over and above the fall evident in the control protocol. In our previous studies, selective and independent 84-pmol/l increases in arterial and portal vein insulin suppressed TDGP by 5.2 and 4.4 µmol · kg Ϫ1 · min Ϫ1 (by 180 min), respectively, relative to a control study. Obviously, the effects of combined increases in peripheral and portal vein insulin were not additive in suppression of TDGP (relative to the control study). When portal insulin was selectively raised in our previous study, glycogenolysis was completely inhibited. During the selective increase in peripheral insulin, 1.8 µmol · kg Ϫ1 · min Ϫ1 of the decrease in NHGO was due to an inhibition of glycogenolysis (resulting from the increase in hepatic sinusoidal insulin that resulted from the rise in arterial insulin) and 1.8 µmol · kg Ϫ1 · min Ϫ1 was due to the redirection of glycogenolytically derived carbon to lactate. In the present experiments, neither of the latter would be expected to occur in response to the increment in peripheral insulin, since the increase in hepatic sinusoidal insulin resulting from the concurrent increase in peripheral and portal insulin was greater (60%) than the increase previously experienced and would have inhibited glycogenolysis completely. Thus, in the Combo group, one would have expected an inhibition of glycogenolysis (ϳ4.4 µmol · kg Ϫ1 · min Ϫ1 ) along with a fall in net hepatic gluconeogenesis (1.6 µmol · kg Ϫ1 · min Ϫ1 ), which would have resulted from the rise in peripheral insulin. If the drop in TDGP (2.7 µmol · kg Ϫ1 · min Ϫ1 ) in the Cont group is taken into account, a fall of 8.7 µmol · kg Ϫ1 · min Ϫ1 from baseline would be predicted in the Combo group. The observed TDGP fall in the Combo group was 7.1 µmol · kg Ϫ1 · min Ϫ1 , a value very close to that predicted.
The inability of small increases in insulin to fully suppress TDGP is not an unexpected result. In humans, Katz et al. (16) and Hother-Nielsen et al. (15) found the 50% effective dose for the suppression of HGP by arterial insulin to be ϳ95-165 pmol/l. Bevilacqua et Fig. 2 . Changes in tracer-determined glucose production (TDGP) and net hepatic glucose output (NHGO) in 18-h fasted dogs during basal period (Ϫ40 to 0 min) and during simultaneous equal increases in peripheral and portal vein insulin created during experimental period, as described in text. No change was made in insulin infusion during experimental period in Cont dogs. Data are expressed as group means Ϯ SE. Significant suppression (P Ͻ 0.05) of TDGP and NHGO in Combo group was reached 15 min after simultaneous equal increase in peripheral and portal vein insulin and all points afterwards. Cont group showed a significant suppression of TDGP 30 min into experimental period and thereafter. Significant suppression of NHGO in Cont group was found only at 150 min. Significant differences in NHGO between 2 groups were found at 90, 120, 150, and 180 min. Significant differences in TDGP between 2 groups were found at 30 and 120 min and thereafter. 4) raised arterial insulin 360 pmol/l in humans during euglycemia and found that HGP was suppressed from 66 Ϯ 7 to 15 Ϯ 8 mg·m Ϫ2 · min Ϫ1 by 120 min. In all of the above studies, however, glucagon was either not measured or fell, and this change most likely contributed to the decrease in glucose production. Boden et al. (5) found that an increase in arterial insulin from 30 to 420 pmol/l suppressed HGP from 12.5 to 1.6 µmol · kg Ϫ1 · min Ϫ1 even when the glucagon concentration did not change. In agreement with our data, these previous studies demonstrated that glucose production by the liver, as measured by tracer methodology, is not completely inhibited, even by relatively high insulin concentrations.
NHGO in the Combo group was fully suppressed (9.8 to 0.0 µmol · kg Ϫ1 · min Ϫ1 ) by insulin infusion. Because NHGO represents the net movement of glucose into and out of the liver, and since TDGP fell to only 5.3 µmol · kg Ϫ1 · min Ϫ1 , the suppression of NHGO must have resulted in part from an increase in hepatic glucose uptake. The difference between TDGP (5.3 µmol · kg Ϫ1 · min Ϫ1 ) and NHGO (0 µmol · kg Ϫ1 · min Ϫ1 ) in the last 30 min of the study provides an estimate of the net amount of glucose taken up by the liver (5.3 µmol · kg Ϫ1 · min Ϫ1 ). To the extent that the kidneys are responsible for a portion of TDGP, this would be an overestimate. In our earlier study (20) , the kidney produced ϳ2.0 µmol · kg Ϫ1 · min Ϫ1 of glucose after an overnight fast in the conscious dog. A study by Cersosimo et al. (7) demonstrated that a selective increase of 51 pmol/l in renal artery insulin could decrease renal glucose output by ϳ73%. Therefore, because the rise in arterial insulin in the Combo group was 102 pmol/l, renal glucose release would be expected to be virtually zero and thus TDGP would be a reflection of glucose release by the liver. The net hepatic [3-3 H]glucose balance data confirm that hepatic glucose uptake was increased during hyperinsulinemia (1.2 basal to 4.2 µmol · kg Ϫ1 · min Ϫ1 by the end of the experiment). Both estimates of hepatic glucose uptake suggest that it was 4-5 µmol · kg Ϫ1 · min Ϫ1 during the increase in insulin.
If glycogenolysis is shut off by the rise in portal insulin as suspected, the carbon produced by the liver as glucose (5.3 µmol · kg Ϫ1 · min Ϫ1 ) and lactate (0.8 µmol · kg Ϫ1 · min Ϫ1 glucose equivalents), as well as the amount theoretically oxidized within the liver (ϳ2.0 µmol · kg Ϫ1 · min Ϫ1 ), must be derived from the gluconeogenic precursors being taken up (2.9 µmol · kg Ϫ1 · min Ϫ1 glucose equivalents) and exogenous glucose extracted Values are group means Ϯ SE for 6 and 5 dogs in the Combo and Cont groups, respectively. Basal period value is the average of the Ϫ40, Ϫ20, and 0 min time points. Significant differences (P Ͻ 0.05) from * basal values and † between groups are noted. ␤-OHB, ␤-hydroxybutyrate; AcAc, acetoacetate; NEFA, nonesterified fatty acid. by the liver. This suggests that glucose uptake by the liver was ϳ5.2 µmol · kg Ϫ1 · min Ϫ1 , again in tune with the above estimates. To the extent that glycogenolysis continued, the need for hepatic glucose uptake would be reduced. Regardless of its absolute value, it is clear that, when insulin was raised in the peripheral circulation and portal vein concurrently, hepatic glucose uptake occurred. Thus the effects of equal 102-pmol/l increases in peripheral and portal vein insulin brought about simultaneously are additive in suppression of NHGO in that they cause a significant movement of glucose into the hepatocyte, which neither causes alone. As noted previously, the latter could be explained by an interaction of the direct and indirect actions of insulin on the liver or by the fact that the simultaneous increase in arterial and portal insulin created a greater rise in the liver sinusoids than when either was increased alone.
During a selective increase in peripheral insulin, net hepatic lactate output increased significantly, whereas NHGO fell (27) . Glycogenolytically derived carbon was redirected through glycolysis to lactate without a net decrease in glycogen breakdown. These changes correlated with a temporal fall in the NEFA level. In fact, when NEFA levels were maintained, the increase in net Net hepatic glycerol uptake, µmol · kg Ϫ1 · min hepatic lactate output did not occur and the fall in NHGO was significantly blunted (28) . A selective increase in portal insulin, on the other hand, suppressed glycogenolysis, failed to alter NEFA levels, and suppressed net hepatic lactate output (27) . In the current studies, when portal and peripheral insulin levels were increased simultaneously, NEFA levels again fell. As a result, net hepatic lactate output again increased significantly 60 min into the experiment and was still increased by 1.8 µmol · kg Ϫ1 · min Ϫ1 at the end of the study. In the control group, net hepatic lactate output decreased progressively, eventually falling by 5.1 µmol · kg Ϫ1 · min Ϫ1 . If the difference between the two groups is converted to an amount of glucose that was broken down to create this amount of lactate, it would equal 3.5 µmol · kg Ϫ1 · min Ϫ1 of glucose equivalents. Interestingly, the significant increase in lactate output correlated temporally with the increase in glucose uptake by the liver. Thus glycolysis was again increased, even though glycogenolysis was inhibited, but in this case the glucose carbon being converted to lactate seems to have been derived from the circulation. The exact biochemical mechanism by which the fall in NEFA levels influences the increase in net hepatic lactate output and net hepatic uptake of glucose is unknown. The fall in NEFA may bring about multiple effects, including potential changes in substrate levels and the redox state of the liver. A fall in citrate levels would activate phosphofructokinase, whereas a change in the mitochondial redox state could activate pyruvate dehydrogenase, both of which could enhance glycolysis and in turn cause lactate dehydrogenase to convert pyruvate to lactate. The difference in activation time of the enzymes may cause the peak in net hepatic lactate output at 1 h and the eventual decrease in lactate output by the end of the experiment.
Other investigators have shown (8, 9 ) that, in euglycemic humans, insulin levels Ͼ600 pmol/l can increase splanchnic glucose uptake slightly (3.9 µmol · kg Ϫ1 · min Ϫ1 ). Similarly, in the dog (21) net hepatic glucose uptake was 3.3 µmol · kg Ϫ1 · min Ϫ1 during euglycemic hyperinsulinemia of 720 pmol/l. No experiments to date have clearly shown that hepatic glucose uptake is increased in response to small changes in insulin (102 pmol/l) under euglycemic conditions. It has been shown, however, that relatively small changes in arterial insulin (144 pmol/l) can result in net hepatic uptake of glucose under hyperglycemic conditions (24) . The results from the current study may be interpreted to indicate that peripheral insulin, working through the suppression of NEFA levels, could play a role in regulating the uptake of glucose by the liver. However, the effect can only occur when hepatic sinusoidal insulin has increased enough to suppress glycogenolysis. The consequences of NEFA suppression under hyperinsulinemic conditions on the movement of glucose into the liver remain to be investigated.
These findings may indicate why other investigators (1, 3, 6) have concluded that insulin's ability to suppress HGP appears relatively slow (ϳ60 min). Insulin appears to have three different effects on the liver, which occur at different times. One action of insulin is an immediate and direct effect on the liver to suppress glycogenolysis. We have previously demonstrated that a selective increase of 84 pmol/l in portal vein insulin rapidly (ϳ15 min) and completely suppresses glycogenolysis (27) . A secondary effect appears dependent on an increase in glucose uptake by the liver, which is maximal at 1 h. In a previous study, Pagliassotti et al. (25) showed that it required 45 min for an effect of insulin on net hepatic glucose uptake to become manifest under hyperglycemic conditions. A third effect appears to be a time-dependent suppression of the gluconeogenic precursor supply to the liver. The sum of these three effects is to create a rapid first-phase suppression of HGP in combination with a slower secondary phase. Therefore, the overall response of HGP to insulin appears to be slow (ϳ60 min). It is important to note that the first phase, which represents a suppression of glycogenolysis, is rapid (ϳ15 min).
In summary, we found that simultaneous equal increases in peripheral and portal vein insulin of 102 pmol/l were not additive in their ability to suppress TDGP. They were, however, additive in their ability to decrease NHGO. The latter occurred because the effects of the changes in insulin were synergistic in increasing the uptake of glucose by the liver. Whether this was due to the greater increase in sinusoidal insulin or the result of a unique response to the combined direct (liver) and indirect (fat) effects of insulin remains to be determined.
